Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Two-Dimensional Infrared Spectroscopy Offers Clues into Amyloid Disease Mechanisms

By BiotechDaily International staff writers
Posted on 04 Aug 2014
Image: Schematic of the intermediate structure in the aggregation pathway of amylin (Photo courtesy of Zhang, Buchanan, Zanni, Biomedical Spectroscopy and Imaging).
Image: Schematic of the intermediate structure in the aggregation pathway of amylin (Photo courtesy of Zhang, Buchanan, Zanni, Biomedical Spectroscopy and Imaging).
Amyloid diseases, such as type 2 diabetes, cataracts, Alzheimer’s disease, and the spongiform encephalopathies, all share the common characteristic that proteins aggregate into long fibers that then form plaques. However, recent in vitro research has demonstrated that neither the amylin monomer precursors nor the plaques themselves are very toxic. New data revealed by using two-dimensional infrared (2D IR) spectroscopy shows an intermediate structure during the amylin aggregation pathway that may clarify toxicity, offering new strategies for interventions.

The findings were published in the online July 1, 2014, in the journal Biomedical Spectroscopy and Imaging. “Figuring out how and why amyloid plaques form is exceedingly difficult, because one needs to follow the atomic shapes of the protein molecules as they assemble. Most tools in biology give either shapes or motions, but not both. We have been developing a new spectroscopic tool, called two-dimensional infrared spectroscopy, which can monitor the plaques as they form in a test tube,” said lead investigator Martin T. Zanni, PhD, from the department of chemistry at the University of Wisconsin-Madison (USA).

The researchers utilized this new technology to study the amyloid protein associated with type 2 diabetes. Isotope labeling was used to measure the secondary structure content of individual residues. By following many 2D IR spectra from one particular region (known as the FGAIL region) over several hours, they were able to visualize the amylin as it progressed from monomers to fibers.

“We learned that, prior to making the plaques, the proteins first assemble into an unexpected and intriguing intermediate and organized structure,” commented Dr. Zanni. The proteins undergo a transition from disordered coil (in the monomer), to ordered β-sheet (in the oligomer) to disordered structure again (in the fiber).

These findings help to elucidate the physics of the aggregation process, the chemistry of amyloid inhibitors, and the biology of type 2 diabetes, as well as elucidate earlier contradictory data.

The scientists suggest that differences between species in their capacity to develop type 2 diabetes may be related to the capacity to form these intermediate amylin structures. That may be why humans develop the disease while dogs and rats do not. “I am not encouraging us to begin engineering our DNA to match that of rats, but our findings may help to develop plaque inhibitors or hormone replacement therapies for people suffering from type 2 diabetes, because we know the structure we want to avoid,” said Dr. Zanni. He added that mutations in the FGAIL region may inhibit fiber formation by interfering with the formation of these intermediates.

Related Links:

University of Wisconsin-Madison



SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.